KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Jan 15, 2025 >>  ABB India 6185  [ 0.55% ]  ACC 1967  [ 1.02% ]  Ambuja Cements 519.25  [ 0.78% ]  Asian Paints Ltd. 2228.6  [ -0.50% ]  Axis Bank Ltd. 1027.35  [ -2.14% ]  Bajaj Auto 8570  [ -0.53% ]  Bank of Baroda 221.95  [ -0.89% ]  Bharti Airtel 1607.95  [ 0.50% ]  Bharat Heavy Ele 202.25  [ 2.51% ]  Bharat Petroleum 267.15  [ -1.24% ]  Britannia Ind. 4874.05  [ 0.18% ]  Cipla 1446.9  [ -0.08% ]  Coal India 374.5  [ 1.39% ]  Colgate Palm. 2669  [ -1.52% ]  Dabur India 514.7  [ 0.34% ]  DLF Ltd. 735.25  [ 1.79% ]  Dr. Reddy's Labs 1339.2  [ 0.14% ]  GAIL (India) 178  [ 1.19% ]  Grasim Inds. 2319.45  [ 0.32% ]  HCL Technologies 1825.9  [ 0.66% ]  HDFC Bank 1642.75  [ -0.09% ]  Hero MotoCorp 4111.9  [ 0.15% ]  Hindustan Unilever L 2381.25  [ 0.57% ]  Hindalco Indus. 591.05  [ 0.00% ]  ICICI Bank 1238.45  [ -0.06% ]  IDFC L 108  [ -1.77% ]  Indian Hotels Co 813.35  [ 4.02% ]  IndusInd Bank 961.5  [ 0.05% ]  Infosys L 1949.8  [ 0.54% ]  ITC Ltd. 437.2  [ 0.11% ]  Jindal St & Pwr 910.25  [ 0.03% ]  Kotak Mahindra Bank 1789.3  [ 2.29% ]  L&T 3507.5  [ 1.22% ]  Lupin Ltd. 2128.15  [ -1.26% ]  Mahi. & Mahi 2960.05  [ -2.91% ]  Maruti Suzuki India 11940.6  [ 1.69% ]  MTNL 44.88  [ 0.20% ]  Nestle India 2201.1  [ -0.80% ]  NIIT Ltd. 159.6  [ -3.45% ]  NMDC Ltd. 63.21  [ -0.36% ]  NTPC 321.25  [ 3.35% ]  ONGC 258.15  [ -0.83% ]  Punj. NationlBak 98.25  [ -0.35% ]  Power Grid Corpo 298.8  [ 3.03% ]  Reliance Inds. 1252.3  [ 1.11% ]  SBI 754  [ 0.79% ]  Vedanta 435.2  [ 1.06% ]  Shipping Corpn. 193.25  [ -0.34% ]  Sun Pharma. 1758  [ -0.61% ]  Tata Chemicals 964.45  [ -0.08% ]  Tata Consumer Produc 955  [ -0.85% ]  Tata Motors 763.45  [ -0.93% ]  Tata Steel 126.55  [ -0.35% ]  Tata Power Co. 365.5  [ 2.34% ]  Tata Consultancy 4248.55  [ 0.35% ]  Tech Mahindra 1673.9  [ 1.62% ]  UltraTech Cement 10549.8  [ 0.67% ]  United Spirits 1412.45  [ 0.41% ]  Wipro 292.55  [ -0.12% ]  Zee Entertainment En 122.5  [ -1.65% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....

Forex

  • Loading....

CELESTIAL BIOLABS LTD.

11 March 2020 | 12:00

Industry >> Bio Technology

Select Another Company

ISIN No INE221I01017 BSE Code / NSE Code 532871 / CELESTIAL Book Value (Rs.) 1.23 Face Value 10.00
Bookclosure 23/05/2024 52Week High 6 EPS 0.00 P/E 0.00
Market Cap. 3.95 Cr. 52Week Low 2 P/BV / Div Yield (%) 1.42 / 0.00 Market Lot 1.00
Security Type Other

History of Company

The company history sections lists out major chronological events that happened to the company.
CELESTIAL LABS LIMITED was incorporated as a Private Limited Company on November 19, 1997 as "Celestial Technologies Private Limited". The subscribers to the memorandum were Mr. Rajani Kanth Katragadda and Mr. Vijay Marur. The company was later converted into a Public Limited Company under the name "Celestial Technologies Limited" on December 6, 1999 and has been subsequently renamed as "CELESTIAL LABS LIMITED" effective from February 13, 2004. The present promoter of the company is Mr. Aditya Narayan Singh. The Original promoters sold their holding to the present promoter on 7.11.1998.

CELESTIAL LABS LIMITED is a Hyderabad based ISO 9001-2000 certified company. It has been providing customized enterprise solutions, bioinformatics services and also involved in development of biopharmaceuticals and industrial enzymes. CELESTIAL LABS is in contact with Centre for Cellular & Molecular Biology (CCMB) under the aegis of Council for Scientific and Industrial Research, Ministry of Science and Technology, Government of India and Indian Institute of Chemical Technology (IICT), premier chemical and Biological Institutions in Hyderabad to work on collaborative research projects to be funded by Department of Science and Technology New Delhi. The in-house research and development centre of CELESTIAL LABS is recognized by the Department for Scientific and Industrial Research, Ministry of Science and Technology, New Delhi.

Major Events in the history of the Company are given below:

Year Event 1997 Incorporation of Company 1999 Conversion of Private Limited Company to Public Limited Company and Change of Management . 2004 ISO Certification 2004 Development of a denovo drug design tool" CELSUITE" 2004 Change of name from Celestial Technologies Limited to Celestial Labs Limited 2004 Developed a bio-molecule to treat Vitiligo 2005 Designed a bio-molecule to treat multi cancer

The company has developed a de novo drug design tool "CELSUITE" to aid the pharma industry in discovering new molecules for curing different diseases. This tool will enable the company not only to design new molecules for its own purpose but also to provide the bio-informatics services to the various pharma and biotech companies. This tool has filed for protection of the IPR under the Copy Right Act vide Dairy no 147-151 /05 on 20.06.2005 to the department.

Based on the company's in silico expertise (applying bioinformatics tools), the company has developed therapeutic molecules to treat Leucoderma and multiple cancers. The cloned molecules are being subjected for purification by the wet lab procedures at the company's collaborative Institute, Department of Microbiology, Osmania University, Hyderabad.

In the industrial biotechnology area, the company has signed the technology transfer agreement with IMTECH Chandigarh (a very reputed Council of Scientific & Industrial Research organization) for the manufacture of two industrial enzymes - alpha Amylase and alkaline Protease. Initially these would be marketed in India and later overseas.

The company has initiated setting up of a biotechnology facility to develop its drug molecules and manufacture industrial enzymes. This facility would also include the research laboratories for carrying out further R & D activities to develop new related products for reducing wrinkles / stretch marks and acceleration of wound healing from the same chemical structure of vitiligo. The proposed facility will be set up at Shapoorji Pallonji Biotech Park in Genome Valley at Hyderabad in Andhra Pradesh.

The company has also plans to cater to the laboratory process outsourcing by using innovative platform technologies/services in the field of analytical laboratory and bio-computational systems. The company is positioned to drive innovations and support activities in post genome advancements via clinical trials (CT) and laboratory process outsourcing (LPO) to be a significant player in personalized medicine in select disease areas.

2009

- Celestial Labs Ltd has informed that the Board of Directors of the Company by a resolution passed by circulation has appointed Mr. Subhash C Srivastava as an Additional Director of the Company w.e.f. April 15, 2009.

-Company has changed its name from Celestial Labs Ltd. to Celestial Biolabs Ltd.

2012 --Registered Office of the Company has been shifted from Plot # 231A, MLA Colony, Road # 12, Banjara Hills, Hyderabad- 500034 to Plot No. 59, Road No. 12, APIIC Tech Park, IDA Nacharam, Hyderabad - 500076 2013 -Celestial Biolabs Ltd Launching of New Product - "Cadalmin GAe"

2014 -Celestial Biolabs Ltd Hyderabad has launched Cadalmin Gae, a marine derived, developed, formulated clinically tested and patented natural product to treat arthritis (all kinds of joint pain). -Celestial Biolabs launches new drug to treat arthritis

2015 -"Celestial To Launch Patented Anti-Diabetic Product". -Drug maker Celestial Biolabs Ltd has successfully completed pre-clinical study on mouse for finding out toxicity and efficacy for Herbal Biovita, a health drink.

2018 -Celestial Biolabs Limited has informed the Exchange regarding a press release dated August 23, 2018, titled "Launching of new product".